Àü¸³¼±ºñ´ëÁõ¿¡ ´ëÇÑ ÃÖ¼Òħ½À ¼ö¼úÀû Ä¡·áÀÇ È¿°ú ¹× ¾ÈÀü¼º¿¡ ´ëÇÑ Ã¼°èÀû °íÂû
The Systematic Review of the Efficacy and Safety of Minimally Invasive Surgical Treatments in Benign Prostatic Hyperplasia
À̹ÎÈ£, ½ÅÀ¯¼·, °¨¼ºÃ¶,
¼Ò¼Ó »ó¼¼Á¤º¸
À̹ÎÈ£ ( Lee Min-Ho )
°æ»ó´ëÇб³ ÀÇ°ú´ëÇРâ¿ø°æ»ó´ëÇб³º´¿ø ºñ´¢ÀÇÇаú
½ÅÀ¯¼· ( Shin Yu-Seob )
ÀüºÏ´ëÇб³º´¿ø ºñ´¢ÀÇÇаú
°¨¼ºÃ¶ ( Kam Sung-Chul )
°æ»ó´ëÇб³ ÀÇ°ú´ëÇРâ¿ø°æ»ó´ëÇб³º´¿ø ºñ´¢ÀÇÇаú
Abstract
Lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH) has conventionally treated by transurethral resection of the prostate (TURP) or open simple prostatectomy. TURP has historically been associated with significant morbidity and then holmium laser enucleation of the prostate technique was developed and rapidly extended in global. Over recent years, novel minimally invasive surgical treatments (MISTs) such as the prostatic urethral lift (Urolift system), convective Water Vapor Energy (REZUM system), Aquablation (Aquabeam system) were entered to the field of BPH. MISTs aim to be effective, ideally to be performed in an outpatient setting under only local anesthesia and to offer a more favorable safety results than existing techniques. In present study, we provide an update on the more recently and largely studied about MISTs. The mechanism of action, efficacy and safety profiles about these MISTs in clinical trials were evaluated and presented.
Å°¿öµå
Efficiency; Lower urinary tract symptoms; Minimally invasive surgical procedures; Prostatic hyperplasia; Safety
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸